Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to EPI-321 for the treatment of facioscapulohumeral muscular dystrophy (FSHD), the most common form of muscular dystrophy in adults. EPI-321 is an investigational therapy being developed as a potential single-dose treatment to suppress abnormal expression of the DUX4 gene.
Epic plans to initiate a first-in-human, phase 1/2 clinical study of EPI-321 in the first half of 2024. The multi-center study will be designed to assess the safety, activity, and preliminary efficacy of EPI-321 in individuals with FSHD.
“We are pleased the FDA has recognized the unmet need of those living with FSHD by granting this Orphan Drug Designation, and we believe EPI-321 could serve as an important new therapeutic option for these patients,” said Weston Miller, M.D., chief medical officer of Epic Bio. “We are working diligently to advance EPI-321 toward the clinic, and we look forward to generating meaningful clinical data to inform its future development as a potential new treatment for FSHD.”
The FDA has the authority to grant Orphan Drug Designation to therapies to prevent, diagnose or treat a rare disease or condition, defined as those affecting fewer than 200,000 people in the United States. The designation qualifies drug developers for certain financial benefits, including tax credits, prescription drug user fee waivers, and a potential period of 7 years of market exclusivity should EPI-321 receive marketing approval in the US.
FSHD is a rare genetic muscle disease which affects approximately 4.6 in 100,000 people worldwide, and which currently has no cure. It is caused by a genetic mutation leading to aberrant expression of the DUX4 gene. FSHD affects both females and males; 90 percent of patients’ symptoms manifest before the age of 201. The disease varies in severity and can manifest in progressive muscle weakness and tissue atrophy in the face, shoulders, upper arms, and lower legs. Twenty-five percent of people with FSHD will require a wheelchair by the age of 502.
EPI-321 is an investigational epigenetic therapy that aims to address the underlying molecular mechanisms of FSHD by restoring methylation to the D4Z4 region of chromosome 4 and halting toxic expression of the DUX4 gene. EPI-321 is delivered to muscle tissue within a single AAV vector (AAVrh74) which has been clinically validated for muscle delivery. Preclinical studies on EPI-321 have demonstrated its ability to robustly suppress pathological expression of the DUX4 gene and reduce muscle cell death.
Epic Bio is a leading epigenetic editing company, leveraging the power of CRISPR without cutting DNA. The company’s proprietary Gene Expression Modulation System (GEMS) includes the smallest Cas protein known to work in human cells, enabling in vivo or ex vivo delivery via a single viral vector.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!